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Multiple myeloma (MM) is a plasma cell malignancy localized in the bone marrow. Despite the introduction of novel therapies
majority of MM patients relapse. We have previously shown that inhibition of P-selectin and P-selectin glycoprotein ligand-1 (PSGL1) play a key role in proliferation of MM and using small-molecule inhibitors of P-selectin/PSGL-1 sensitized MM cells to therapy.
However, these small-molecule inhibitors had low specificity to P-selectin and showed poor pharmacokinetics. Therefore, we tested
blocking of P-selectin and PSGL-1 using functional monoclonal antibodies in order to sensitize MM cells to therapy. We have
demonstrated that inhibiting the interaction between MM cells and endothelial and stromal cells decreased proliferation in MM
cells and in parallel induced loose-adhesion to the primary tumor site to facilitate egress. At the same time, blocking this interaction
in vivo led to MM cells retention in the circulation and delayed homing to the bone marrow, thus exposing MM cells to bortezomib
which contributed to reduced tumor growth and better mice survival. This study provides a better understanding of the biology of
P-selectin and PSGL-1 and their roles in dissemination and resensitization of MM to treatment.

1. Introduction
Multiple myeloma (MM) is a plasma cell malignancy located
mainly in the bone marrow (BM), characterized by continuous dissemination of cancer cells [1, 2]. Accumulating
evidence indicates that egress of MM cells from one site of
the BM to a new site is a complex process that involves cellular
and acellular interactions with endothelial cells, stromal cells,
soluble growth factors, and extracellular matrix. Molecular
mechanisms of cell adhesion and cell trafficking and thus
metastasis in MM have been intensively investigated [3, 4].
The interactions of MM cells with the BM microenvironment
play a crucial role in cell survival, cell trafficking, and
drug resistance in MM; and interrupting these interactions
enhances MM cells sensitivity to chemotherapy [3–7].
Selectins (CD62) are cell surface lectin-like adhesion
molecules which bind sugar polymers and are involved in

lymphocyte extravasation, especially during inflammation
and cancer metastasis [8]. Selectin family consists of E-selectin, L-selectin, and P-selectin, expressed on endothelium,
leukocytes, and platelets, respectively [8]. When endothelium
is activated, P-selectin travels to the cell surface and can
bind to ligands expressed on both leukocytes and cancer
cells. The selectins and ligands interact rapidly in order to
facilitate tethering, followed by rapid dissociation to enable
rolling on the endothelium and ultimately cell extravasation
[9]. P-selectin glycoprotein ligand-1 (PSGL-1, CD162) is the
best characterized ligand for all three types of selectins and
is expressed on myeloid, lymphoid, and dendritic cells [10].
PSGL-1 undergoes posttranslational modifications which are
required to bind selectins and are similar for binding Pselectin and L-selectin [11]. PSGL-1 has especially high affinity
for P-selectin on intact leukocytes compared to other ligands
and is essential for adhesion to P-selectin [12, 13].
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During cancer metastasis, cell adhesion and cell migration are frequently malfunctioning. Since cancer cells mimic
leukocytes exploiting selectin-dependent mechanisms to
extravasate, there is a growing interest in blocking selectins
and their ligands in inflammation, tumor progression, and
metastasis [14–16]. In solid tumors, it was demonstrated that
absence or blocking of P-selectin with antibody decreased
tumor cell adhesion and metastasis in rat lungs [17], gastric
cancer in mice [18], and colorectal cancer [19].
Both P-selectin and PSGL-1 were also suggested as new
targets in MM [6, 20, 21]. Expression of PSGL-1 was reported
in normal plasma cells, with higher levels of PSGL-1 indicating plasma cell differentiation [6, 22]. PSGL-1 was shown
to be highly expressed in MM biopsies and MM cell lines
[5, 6, 23], and PSGL-1 gene expression increased in the course
of MM progression [6]. Another study performed on MM
biopsies demonstrated a significant correlation between the
degree of PSGL-1 expression and the Durie-Salmon stage;
thus PSGL-1 could be used as a diagnostic marker in MM [21].
It was previously demonstrated that knocking down PSGL-1
with siRNA in MM cells delayed tumor initiation in vivo [6].
Moreover, blocking selectins with pan-inhibitor GMI-1070 in
MM mouse model in combination with bortezomib inhibited
tumor growth during treatment and delayed tumor progression after halting the therapy significantly improving mice
survival [6]. However, this inhibitor was previously shown to
be a potent inhibitor of E-selectin and a nonpotent inhibitor
of P-selectin, with high concentrations needed to inhibit Pselectin [24]. The necessity of using very high concentrations
of GMI-1070 to achieve inhibition of P-selectin-mediated
interactions of MM cells with the BM microenvironment
limits the possibility to translate it into clinical settings. Thus,
there is an urgent need to use novel, specific, and potent Pselectin/PSGL-1 interaction inhibitors.
In this study, we focused on the role of blocking P-selectin
and PSGL-1 to inhibit MM progression and dissemination
using specific humanized blocking antibodies for P-selectin
and PSGL-1. We tested MM cell adhesion and proliferation in vitro, as well as MM cells extravasation, homing,
tumor growth, and mice survival in vivo. These studies
emphasize the importance of targeting P-selectin and PSGL1, in combination with bortezomib, in the context of BM
microenvironment, as a promising therapy for MM patients.

2. Materials and Methods
2.1. Cell Culture. The MM cell lines (MM1.s and H929,
mycoplasma-negative) were obtained from American Type
Culture Collection (ATCC, Rockville, MD). MM cell lines
were cultured in RPMI-1640 media (Corning CellGro,
Mediatech, Manassas, VA) supplemented with 10% fetal
bovine serum (FBS, Gibco, Life Technologies, Grand Island,
NY), 2 mmol/L of L-glutamine, 100 U/mL Penicillin, and
100 𝜇g/mL Streptomycin (CellGro, Mediatech, Manassas,
VA). Human umbilical vein endothelial cells were purchased from Lonza, Allendale, NJ. Human stromal cells
were obtained from MM patients’ BM biopsies depleted of
CD138-positive myeloma plasma cells. Endothelial cells were
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cultured in endothelial cell growth media (EGM-2, Lonza)
and stromal cells were cultured in 20% FBS Dulbecco’s Modified Eagle’s Medium (Corning CellGro, Mediatech, Manassas,
VA) containing L-glutamine, Penicillin/Streptomycin. Cells
were cultured at 37∘ C (5% CO2 ) in the NuAire water jacket
incubator (Plymouth, MN).
2.2. Animals. SCID-beige mice (females, 8-week old) and
Balb/C mice (females, 9-week old) were obtained from
Charles Rivers Laboratories (Wilmington, MD). Approval for
these studies was obtained from the Ethical Committee for
Animal Experiments at Washington University in St. Louis
Medical School.
2.3. Effect of SelG1 and SelK2 on MM Cell Adhesion and
Proliferation. The humanized monoclonal antibodies anti-Pselectin (SelG1) and anti-PSGL-1 (SelK2) were obtained from
Selexys Pharmaceuticals (Oklahoma City, OK). For adhesion
assay, endothelial and stromal cells (3 × 103 cells per well
in 96-well plate) were incubated with SelG1 (10 𝜇g/mL) and
MM cells prelabeled with calcein-AM of final concentration
1 𝜇g/mL (Invitrogen, Life Technologies, Grand Island, NY)
were incubated with SelK2 (10 𝜇g/mL). MM cells were applied
to unlabeled endothelial cells or stromal cells for 1 hr, nonadherent cells were aspirated, and adherent cells were measured
by detecting the fluorescent intensity signal using fluorescent
reader (excitation/emission = 485/520 nm). For proliferation
assay, H929 prelabeled with DiD (Invitrogen) were cultured
alone, with endothelial or stromal cells, and were treated with
or without bortezomib (Selleck Chem, Houston, Texas), in
presence or absence of SelG1 and SelK2 antibodies, and cell
proliferation was determined by flow cytometry.
2.4. Effect of SelG1 and SelK2 on MM Cell Extravasation
and Homing. MM1.s labeled with calcein-AM were injected
intravenously (IV) into Balb/C mice (3 × 106 cells/mouse)
creating 3 groups: (1) mice treated with anti-mouse P-selectin
antibody injected intraperitoneally (IP) the day before (𝑛 =
3); (2) mice treated with anti-mouse PSGL-1 antibody (rat
anti-mouse CD162 antibody, catalog number 557787, BD
Pharmingen, San Jose, CA) injected IP the day before and
MM1.s treated with SelK2 antibody (anti-human PSGL-1)
for 1 hr prior to the injection (𝑛 = 3); or (3) untreated
MM1.s (𝑛 = 3). 50 𝜇L of blood was collected from the
portal vein at 50 min after injection, red blood cells were
lysed with a buffer (BioLegend, San Diego, CA), and the
circulating calcein-AM-positive MM cells were counted by
flow cytometry. The presence of MM cells in the circulation
signified retention, or in other words the absence of these
cells in the circulation signified extravasation of the MM
cells. After the last blood aspiration, mice were sacrificed;
mononuclear cells were isolated from femurs, washed, and
analyzed by the flow cytometry. The number of calcein-AMpositive cells was analyzed in each mouse and reflected the
number of MM cells which homed to the BM.
2.5. Tumor Progression and Survival Study. MM1.s cells were
genetically engineered to express green fluorescent protein
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(GFP) and luciferase (Luc), as described previously [25].
In the first experiment, human MM1.s-GFP-Luc cells were
injected into 24 SCID mice IV at a concentration of 2 × 106
cells per mouse and allowed to grow for 3 weeks. The mice
were then divided randomly into 3 groups (8 mice/group)
and treated as follows: (1) vehicle control which received
PBS as vehicle; (2) anti-mouse P-selectin antibody (5 mg/kg)
(rat anti-mouse CD62P antibody, catalog number 553741, BD
Pharmingen, San Jose, CA) to inhibit P-selectin in the mouse
stroma and endothelium; and (3) SelK2 and anti-mouse
PSGL-1 (5 mg/kg) (catalog number 557787, BD Pharmingen) to inhibit PSGL-1 on human MM cells and in the
mouse microenvironment, respectively. Tumor progression
was monitored by bioluminescence imaging (BLI) once a
week for 4 weeks (week 3 = time 0). In the second experiment,
human MM1.s-GFP-Luc cells were injected into 32 SCID
mice IV at a concentration of 2 × 106 cells per mouse and
allowed to grow for 2 weeks. The mice were then divided
randomly into 4 groups (8 mice/group) and treated as follows:
(1) vehicle control; (2) bortezomib alone (1 mg/kg); (3) bortezomib (1 mg/kg) + anti-mouse P-selectin antibody (5 mg/kg);
and (4) bortezomib (1 mg/kg) + SelK2 and anti-mouse PSGL1 (5 mg/kg). Tumor progression was monitored by BLI twice
a week for 4 weeks (week 2 = time 0). In both experiments,
the vehicle, bortezomib, and antibodies were injected IP twice
a week. Bortezomib and antibodies were administered IP
sequentially twice a week. Tumor progression was followed
twice a week using bioluminescence imaging. Survival of
mice was followed every day by investigator, with no blinding.
2.6. Statistical Analysis. The in vitro experiments shown on
Figures 1 and 3 were performed in quadruples and replicated
independently two more times. Results are shown as mean ±
s.d. The in vivo experiments, also depicted as mean ± s.d.,
were analyzed using student 𝑡-test (Figure 2) or chi-squared
test (Figure 4) for independence for statistical significance,
with the data meeting the assumption of the tests such as
normal distribution. Variation within each group was equally
variant and similar between the groups that were statistically
compared. Values were considered significantly different for
𝑝 value less than 0.05.

3. Results
3.1. P-Selectin and PSGL-1 Regulate Adhesion of MM Cells
to Endothelial and Stromal Cells. First, we tested different
concentrations (2.5, 5.0, and 10 𝜇g/mL) of SelG1 (Figure 1(a))
or SelK2 (Figure 1(b)) on MM cell adhesion to endothelial
and stromal cells and we found a dose-dependent effect
of these monoclonal antibodies. Next, we examined the
adhesion of MM cells (H929 and MM1.s) to stromal and
endothelial cells. We found that after blocking P-selectin
using a single concentration of SelG1 (10 𝜇g/mL) on stromal
cells H929 adhesion was decreased by 60% and MM1.s by
20% (Figure 1(c)); or on endothelial cells H929 adhesion
was decreased by 43% and MM1.s by 23% (Figure 1(d)).
Likewise, after blocking PSGL-1 on MM cells using a single
concentration of SelK2 (10 𝜇g/mL), H929 cell adhesion was
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decreased by 50% and MM1.s by 12% in coculture with stromal cells (Figure 1(e)), or H929 cell adhesion was decreased
by 28% and MM1.s by 40% in coculture with endothelial cells
(Figure 1(f)).
3.2. Blocking P-Selectin and PSGL-1 Decrease Extravasation
and Decrease Homing of MM Cells to the BM In Vivo. To
examine the role of P-selectin and PSGL-1 interaction on
extravasation and homing of MM cancer cells to the BM
in vivo, we injected MM cells labeled with calcein-AM and
detected the number of calcein-AM-positive cells both in
the blood and the BM samples 50 minutes after injection,
indicating extravasation and homing, respectively. In mice
pretreated with anti-mouse P-selectin antibody, MM cells
displayed delayed extravasation with approximately 2.7-fold
more MM cells still present in the circulation, whereas, in
mice pretreated with anti-mouse PSGL-1 antibody and antihuman SelK2, there were 1.4-fold more MM cells in the
circulation compared to untreated mice at time 50 minutes
(Figure 2(a)). In case of homing, pretreatment with antimouse P-selectin antibody decreased the number of MM cells
that had homed to the BM by 82%, whereas in mice pretreated
with anti-mouse PSGL-1 antibody and SelK2 homing was
decreased by 42%, compared to untreated mice (Figure 2(b)).
3.3. P-Selectin and PSGL-1 Affect Proliferation of MM Cells
Cocultured with Endothelial and Stromal Cells. It was demonstrated before that the interaction between BM microenvironment and MM cells contributes to drug resistance [4].
Here we investigated the effect of inhibiting the interaction
between P-selectin and PSGL-1 on MM cell proliferation
detected by flow cytometry. The stroma and endothelial cellinduced proliferation of H929 was decreased using SelG1
or SelK2. Similar effects were observed when combining
the antibodies with bortezomib, in which SelG1 or SelK2
enhanced the effect of bortezomib on H929 proliferation
when cocultured with endothelial cells (Figure 3(a)) and
stromal cells (Figure 3(b)).
3.4. Inhibition of P-Selectin in Combination with Bortezomib
Decreases Tumor Size and Improves Survival in MM Mouse
Model In Vivo. Finally, we studied the effect of blocking
P-selectin and PSGL-1 on MM tumor progression in MM
xenograft mouse model in combination with bortezomib.
MM tumors were established in SCID mice and one week
before bortezomib initiation, two groups of mice were pretreated twice a week with P-selectin and PSGL-1 antibodies.
The combination of P-selectin antibody with bortezomib
inhibited tumor growth significantly, compared to vehicle
control and bortezomib alone treated mice. On the other
hand, combination of PSGL-1 antibody with bortezomib
delayed tumor growth to similar extent as bortezomib alone
(Figure 4(a)). Survival study revealed that mice treated with
P-selectin antibody (but not PSGL-1 antibody) in combination with bortezomib had significantly prolonged survival compared to other groups (Figure 4(b)). Moreover, we
found that inhibiting P-selectin or PSGL-1 alone does not
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Figure 1: P-selectin and PSGL-1 regulate adhesion of MM cells to endothelial and stromal cells in vitro. Endothelial and stromal cells were
treated with increasing concentrations of SelG1 antibody (2.5, 5, and 10 𝜇g/mL) followed by adhesion of H929 or MM1.s cells labeled with
calcein-AM. MM cell adhesion was assessed as a signal of adherent calcein-AM-positive MM cells measured by fluorescent reader and
normalized to untreated cells (a). Likewise, H929 or MM1.s cells labeled with calcein-AM were incubated with increasing concentrations
of SelK2 antibody (2.5, 5, and 10 𝜇g/mL) and plated on untreated endothelial and stromal cells, and the cell adhesion was measured as above
(b). Stromal (c) and endothelial cells (d) were treated with SelG1 (10 𝜇g/mL) for 1 hr followed by plating MM1.s and H929 labeled with calceinAM, and the adhesion was assessed as a signal of adherent calcein-AM-positive MM cells measured by fluorescent reader and normalized to
untreated cells. Likewise, MM1.s and H929 were treated with SelK2 (10 𝜇g/mL) for 1 hr and plated on stromal (e) or endothelial cells (f), and
the cell adhesion was measured as above. Values were considered significant for ∗ 𝑝 < 0.05.

influence tumor progression (Figure 4(c)) and mice survival
(Figure 4(d)), compared to untreated mice.

4. Discussion
MM is characterized by continuous dissemination of cancer
cells throughout the BM [1, 2]. During metastasis in MM,
adhesion of cancer cells to vascular wall requires the presence
of P-selectin on the endothelium and stroma and PSGL1 on cancer cells [6]. It was demonstrated that PSGL-1 is
highly expressed on MM cells and regulates adhesion and cell
trafficking in MM; these interactions involve both endothelial

and BM stroma cells which express high levels of P-selectin
[6]. PSGL-1 was previously suggested as a novel target for
immunotherapy in MM using monoclonal antibody, where
anti-PSGL-1 antibody increased cell death of MM cells in
a time- and dose-dependent manner [26]. Loss-of-function
study and a small molecule pan-selectin inhibitor GMI1070 demonstrated that PSGL-1 and P-selectin regulate the
activation of integrins, adhesion, and proliferation, as well as
downstream signaling. The anti-pan-selectin treatment using
GMI-1070 sensitized MM cells to bortezomib in vitro and
in vivo, controlling growth, dissemination, and drug resistance of MM in the context of the BM microenvironment.
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for ∗ 𝑝 < 0.05.
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Figure 4: Inhibition of P-selectin in combination with bortezomib decreases tumor size and improves survival in MM mouse model in
vivo. The effect of P-selectin and PSGL-1 inhibition on sensitivity to bortezomib of the MM-bearing mice. SCID mice (𝑛 = 8 per group)
were injected with MM1.s-GFP-Luc and tumor growth was determined by bioluminescence imaging (BLI). In the first experiment (c and d),
tumor was allowed to grow for 3 weeks. The mice were then divided into 3 groups: (1) vehicle control; (2) anti-mouse P-selectin antibody
(5 mg/kg); and (3) SelK2 and anti-mouse PSGL-1 (5 mg/kg). Tumor progression was monitored by BLI once a week for 4 weeks (week 3 = time
0). In the second experiment (a and b), tumor was allowed to grow for 2 weeks and then the mice were divided randomly into 4 groups: (1)
vehicle control; (2) bortezomib alone (1 mg/kg); (3) bortezomib (1 mg/kg) + anti-mouse P-selectin antibody (5 mg/kg); and (4) bortezomib
(1 mg/kg) + SelK2 and anti-mouse PSGL-1 (5 mg/kg). Tumor progression was monitored by BLI twice a week for 4 weeks (week 2 = time 0).
Tumor progression was detected shown as region of interest (ROI) normalized to initial tumor size in each group; the statistical significance
was assessed by student 𝑡-test. The statistical significance was present between groups: vehicle versus bortezomib (𝑝 = 0.0025), vehicle versus
P-sel + bortezomib (𝑝 = 0.0023), vehicle versus PSGL-1 + bortezomib (𝑝 = 0.01), bortezomib versus P-sel + bortezomib (𝑝 = 0.0018), and
P-sel + bortezomib versus PSGL-1 + bortezomib (𝑝 = 0.0172) (a). Survival of mice was followed 40 days after starting the treatment and
depicted as Kaplan-Meier curve. The 𝑝 values were calculated from the chi-squared test for independence. The statistical significance was
present between groups: vehicle versus P-sel + bortezomib (𝑝 = 0.005) and bortezomib versus P-sel + bortezomib (𝑝 = 0.01) (b).

However, low specificity of GMI-1070 to P-selectin and its
pharmacokinetic profile with a very short half-life may hold
up further usage of this drug [6].
In the present study, we examined the effect of potent
humanized monoclonal antibodies targeting P-selectin and
PSGL-1, and we confirmed that both antibodies decreased
MM cell adhesion to endothelial and stromal cells. Since
the MM cells in the presence of SelG1 and SelK2 were
less adhesive in vitro, we tested the blocking effect of these
antibodies on cell extravasation in vivo and we found that

inhibiting the interaction of P-selectin and PSGL-1 prevented
MM cell extravasation and increased their circulation time
in vivo. At the same time, blocking P-selectin and PSGL1 significantly decreased the capability of cancer cells to
home to the BM in vivo. These results are in agreement
with our previous studies showing that inhibition of the
interaction using siRNA downregulation of the genes or
the small molecule inhibitor reduced the adhesion of MM
cells to endothelial and stromal cells in vitro and prevented
extravasation and homing to the BM in vivo [6].
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Next, we studied the effect of P-selectin and PSGL-1
antibodies on proliferation of MM cells when cocultured with
endothelial or stromal cells. Results showed that inhibition of
the interaction of MM cells with stromal and endothelial cells
using the anti-P-selectin (SelG1) and the anti-PSGL-1 (SelK2)
antibodies reversed the stromal and endothelial cell-induced
proliferation of MM cells. Similarly, the antibodies increased
the sensitivity of MM cells to bortezomib when these were
cocultured with stromal and endothelial cells. These results
confirm that blocking the P-selectin/PSGL-1 sensitizes MM
cells to chemotherapy.
We then tested the effect of blocking P-selectin on the
BM microenvironment and blocking PSGL-1 on MM cells
on proliferation and drug resistance of MM cells in vivo.
The antibodies alone did affect neither tumor growth nor
mice survival; this is in agreement with our previous findings
that GMI-1070 alone did not induce any delay in tumor
progression in vivo. However, we found that inhibition of the
interaction between PSGL-1 and P-selectin using the humanized antibodies, SelG1 and SelK2, induced sensitization of
MM cells to bortezomib, increased the survival of animals
with MM, and delayed tumor progression. The combination
of bortezomib with the anti-P-selectin antibody SelG1 was
more effective than the combination of bortezomib with
the anti-PSGL-1 antibody SelK2. The possible mechanism
for delayed tumor growth could be prolonged circulation
and exposure of cancer cells in the peripheral blood to
bortezomib due to increased cell retention and reduced cell
homing. In addition, it was demonstrated previously that
PSGL-1 and selectins are involved in macrophage-mediated
drug resistance in MM; by blocking PSGL-1 in MM cells
with antibody or by silencing PSGL-1 with shRNA using
lentiviral vector, MM cells were resensitized to melphalan
when cocultured with macrophages, which was driven by
Erk1/2 pathway activation and c-myc upregulation [23].
In conclusion, our results demonstrate that inhibition of
P-selectin/PSGL-1 axis using humanized monoclonal antibodies, SelG1 and SelK2, is promising as a treatment for
MM and that these antibodies were potent (only 5 ug/mL
was needed) with a very good pharmacokinetics (antibodies
were injected twice a week only). The use of the antibodies disrupted the interaction between MM cells and BM
microenvironment, decreased proliferation and adhesion of
MM cells in vitro, and delayed tumor growth and extended
survival in MM xenograft mouse model. This data provides
a basis for future clinical trials for sensitization of refractory
MM patients to therapy by blocking the P-selectin/PSGL-1
axis using the humanized monoclonal antibodies SelG1 and
SelK2.
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